BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Hu Y, Wang H, Wang M, Gu X, Ping Y, Zeng Q, Li H, Yan J, Yu Z. Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy. Eur J Gastroenterol Hepatol 2020;32:447-53. [PMID: 32012142 DOI: 10.1097/MEG.0000000000001631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dai X, Zeng Y, Zhang H, Gu Z, Gong Q, Luo K. Advances on Nanomedicines for Diagnosis and Theranostics of Hepatic Fibrosis. Adv NanoBio Res 2021;1:2000091. [DOI: 10.1002/anbr.202000091] [Reference Citation Analysis]
2 Li W, Yu X, Chen X, Wang Z, Yin M, Zhao Z, Zhu C. HBV induces liver fibrosis via the TGF-β1/miR-21-5p pathway. Exp Ther Med 2021;21:169. [PMID: 33456536 DOI: 10.3892/etm.2020.9600] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Zhu DM, Xie J, Ye CY, Qian MY, Xue Y. Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy. Can J Gastroenterol Hepatol 2020;2020:8871024. [PMID: 33381476 DOI: 10.1155/2020/8871024] [Reference Citation Analysis]